• Founded: 2011
  • Location: Chicago, IL
  • Employee range: 11 - 50
  • Clinical stage: Clin0
  • Therapy area: Neuropathic pain
  • Drug types: NEU, PN
  • Lead product: SCN9A
  • Product link: https://www.exicuretx.com/science-technology/index.php
  • Funding: $11.5M stock Dec 2021; $27.5M IPO Dec 2019; $13.6M C Jun 2014



job board

Short description:

Spherical Nucleic Acid

Drug notes:

2 partnered programs RD Huntington's, Angelman Syndrome

Long description:

Exicure is developing nucleic acid therapies that target ribonucleic acid targets linked to neurological disorders and hair loss. To develop next-generation nucleic acid therapeutics Exicure is using their proprietary spherical nucleic acid (SNATM) platform. SNAs have a unique chemical structure with synthetic nucleic acid sequences densely radiating from a spherical core. This structure offers advantages over other nucleic acid technologies including unparalleled transfection efficiency into numerous cell and tissue types and multi-targeting capabilities. Exicure’s refined discovery and development process has led them to identify several promising candidates in CNS conditions quickly.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com